Reneo Pharmaceuticals Inc
RPHM | $1.72 -2.83% 16K
|
Professional, Scientific, and T...
(0.0% 1d) (7.3% 1m) (-80.2% 1y) (0.0% 2d) (7.3% 3d) (2.3% 7d) (616.69% volume)
Earnings Calendar: 2024-03-27
Market Cap: $ 57,483,790
https://reneopharma.com
Sec Filling | Patents | 32 employees
Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.
energy renewable genetic metabolic
add to watch list Paper trade email alert is off
Press-releases
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
RPHM | $1.72 -2.83% 16K
|
Professional, Scientific, and T...
|
| O: 0.61%
H: 1.2%
C: 0.0%
business year update pharmaceuticals financial results
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
SGMT | $4.08 0.25% 100K
|
Health Technology
|
| O: 6.65%
H: 18.5%
C: 8.52%
IPSC | $2.965 4.4% 78K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 1.58%
C: -9.48%
RPHM | $1.72 -2.83% 16K
|
Professional, Scientific, and T...
|
| O: -1.81%
H: 4.91%
C: 2.45%
XOMA | News | $24.25 1.7K
|
Health Technology
|
| O: 1.09%
H: 3.51%
C: -4.27%
MIRM | $23.58 -1.13% 31K
|
Health Technology
|
| O: 0.0%
H: 1.61%
C: 0.04%
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 12:00) - globenewswire.com
RPHM | $1.72 -2.83% 16K
|
Professional, Scientific, and T...
|
| O: 0.63%
H: 2.48%
C: 0.0%
VTVT | $24.15 460
|
Health Technology
|
| O: 4.26%
H: 1.74%
C: -3.66%
year update therapeutics financial results
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
Published: 2023-12-14 (Crawled : 14:30) - globenewswire.com
RPHM | $1.72 -2.83% 16K
|
Professional, Scientific, and T...
|
| O: -83.74%
H: 32.54%
C: 6.35%
mavodelpar pharmaceuticals results study
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
Published: 2023-11-13 (Crawled : 12:30) - globenewswire.com
RPHM | $1.72 -2.83% 16K
|
Professional, Scientific, and T...
|
| O: -0.47%
H: 2.51%
C: -1.88%
pharmaceuticals financial results
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
RPHM | $1.72 -2.83% 16K
|
Professional, Scientific, and T...
|
| O: 2.04%
H: 1.75%
C: -0.75%
pharmaceuticals
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
Published: 2023-10-25 (Crawled : 12:00) - globenewswire.com
RPHM | $1.72 -2.83% 16K
|
Professional, Scientific, and T...
|
| O: -0.13%
H: 0.75%
C: 0.19%
presentation pharmaceuticals
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
Published: 2023-10-09 (Crawled : 12:00) - globenewswire.com
RPHM | $1.72 -2.83% 16K
|
Professional, Scientific, and T...
|
| O: -0.12%
H: 8.0%
C: 1.45%
mavodelpar pharmaceuticals study
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)Topline data results from the STRIDE study are expected in December 2023
Published: 2023-10-09 (Crawled : 14:30) - biospace.com/
RPHM | $1.72 -2.83% 16K
|
Professional, Scientific, and T...
|
| O: -0.12%
H: 8.0%
C: 1.45%
mavodelpar expected pharmaceuticals results study
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
Published: 2023-10-06 (Crawled : 12:30) - globenewswire.com
RPHM | $1.72 -2.83% 16K
|
Professional, Scientific, and T...
|
| O: -1.21%
H: 14.34%
C: 12.84%
biotech pharmaceuticals
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 82% | 18% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8258 70.34% 50M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
VTNR S | $1.295 32.25% 5.5M
|
Industrial Services
ALRN | $5.53 30.12% 250K
|
Health Technology
SMSI 4 | $2.53 29.74% 510K
|
Technology Services
HOLO | $2.86 27.68% 28M
|
Last 48 Hours Insiders Buying
TPL P 3 | $591.39 1.1% 15K
|
Miscellaneous
|
15:00
RELL | $10.24 3.85% 36K
|
Electronic Technology
|
13:30
IZEA | $2.53 16K
|
Technology Services
|
00:00
RKT P 383 | $11.735 3.12% 640K
|
Finance
|
22:30
CTRN P 18090 | $23.035 2.97% 16K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% 44K
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.07 -0.58% 840K
|
Health Technology
|
16:30
RMCF | $3.53 1.7K
|
Consumer Non-Durables
|
20:10